Document is current
Any future updates will be listed below
-
Authors
Chatila, Walid K. https://orcid.org/0000-0001-5474-218X
Kim, Jin K. https://orcid.org/0000-0002-4373-1431
Walch, Henry
Marco, Michael R.
Chen, Chin-Tung
Wu, Fan https://orcid.org/0000-0002-3960-320X
Omer, Dana M.
Khalil, Danny N. https://orcid.org/0000-0003-4688-0958
Ganesh, Karuna https://orcid.org/0000-0002-4948-1082
Qu, Xuan
Luthra, Anisha
Choi, Seo-Hyun https://orcid.org/0000-0003-3244-0871
Ho, Yu-Jui
Kundra, Ritika https://orcid.org/0000-0001-6723-2859
Groves, Katharine I.
Chow, Oliver S.
Cercek, Andrea
Weiser, Martin R.
Widmar, Maria
Wei, Iris H. https://orcid.org/0000-0001-9006-9105
Pappou, Emmanouil P.
Nash, Garrett M.
Paty, Philip B. https://orcid.org/0000-0002-7045-2112
Shi, Qian https://orcid.org/0000-0002-4640-8832
Vakiani, Efsevia https://orcid.org/0000-0003-0227-3523
Duygu Selcuklu, S.
Donoghue, Mark T. A.
Solit, David B. https://orcid.org/0000-0002-6614-802X
Berger, Michael F.
Shia, Jinru https://orcid.org/0000-0002-4351-2511
Pelossof, Raphael
Romesser, Paul B.
Yaeger, Rona https://orcid.org/0000-0002-7233-5454
Smith, J. Joshua https://orcid.org/0000-0003-2538-5456
Schultz, Nikolaus https://orcid.org/0000-0002-0131-4904
Sanchez-Vega, Francisco https://orcid.org/0000-0002-2990-4893
Garcia-Aguilar, Julio https://orcid.org/0000-0003-2451-0948
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA090559, K08 CA255574)
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (T32 GM132083)
- License Information
-
More Information
Article History
Received: 24 September 2021
Accepted: 29 June 2022
First Online: 15 August 2022
Competing interests
: D.N.K. has been a consultant for Merck Sharp & Dohme with regard to intellectual property rights and for AbbVie and PsiOxus Therapeutics Ltd with regard to provision of services. E.P.P. has received support from Intuitive Surgical. Q.S. reports a consulting or advisory role with Yiviva, Boehringer Ingelheim Pharmaceuticals, Regeneron Pharmaceuticals, Hoosier Cancer Research Network (to self), an honorarium or speaker role with Chugai Pharmaceutical Co., stocks from Johnson & Johnson, Amgen and Merck & CO. (to self), and research funds from Celgene/BMS, Roche/Genentech, Janssen and Novartis (to institution). D.B.S. has consulted for and received honoraria from Pfizer, Lilly/Loxo Oncology, Vividion Therapeutics, Scorpion Therapeutics and BridgeBio. M.F.B. has consulted for Eli Lilly and PetDx, and has received research funding from Grail not related to the work presented. P.B.R. is an EMD Serono consultant and reports support for travel from Elekta and Philips healthcare and prior research funding from EMD Serono. R.Y. has been an advisor for Pfizer, Mirati Therapeutics and Natera, and has received research support from Pfizer, Boehringer Ingelheim and Forte Biosciences. J.J.S. has received travel support from Intuitive Surgical for fellow education and has served as a clinical advisor for Guardant Health. J.G.-A. has received an honorarium for being a consultant with Medtronics, Ethicon, Johnson & Johnson and Intuitive Surgical, and owns stock in Intuitive Surgical. All other authors have no competing interests.
